ASTH · Astrana Health Inc.

Current Thesis

Astrana Health’s full-risk care thesis depends on delivering its raised profit outlook; the next quarterly report must meet revenue and profit guidance before a weekly close below $34 invalidates the recovery case. The operational test is Q3 revenue of at least $1.000 billion and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of at least $72.5 million, with the FY2026 adjusted EBITDA range of $255–280 million maintained. These thresholds come from the company’s 2026-08-06 guidance. Company results.

The September refresh adds weaker market evidence and a less favorable analyst headline. The supplied adjusted market series records a $37.98 close on 2026-09-11, a three-month decline of 1.7%, and a 14-day relative strength index (RSI) of 38.4. Yahoo Finance’s 2026-09-09 Argus quantitative-report listing says its price target was lowered to $40; the underlying rationale was unavailable. Argus report listing.

As an inference, the narrative is maturing — the 2026-08-06 profit-guidance increase remains the operating anchor, while the 2026-09-11 price measures show no sustained upward momentum. Astrana’s release index still lists the August results as its latest announcement, and its investor calendar lists no upcoming events as checked on 2026-09-13. Those observations do not establish expanding participation. Company announcements, investor calendar.

Bullish and bearish views on Astrana Health Inc.

The model's bull view on Astrana Health Inc. (ASTH), in brief: Profit guidance moved higher. On 2026-08-06, Astrana raised FY2026 adjusted EBITDA guidance to $255–280 million while reaffirming revenue of $3.800–4.100 billion. The evidence supports a higher expected profit contribution without a higher revenue forecast. Company results. Cash… The bear view: Quarterly growth does not prove expansion. Both cases follow in full.

Bull Case

• Profit guidance moved higher. On 2026-08-06, Astrana raised FY2026 adjusted EBITDA guidance to $255–280 million while reaffirming revenue of $3.800–4.100 billion. The evidence supports a higher expected profit contribution without a higher revenue forecast. Company results.
• Cash generation supports reported earnings. For the six months ended 2026-06-30, operating cash flow was $100.8 million and free cash flow was $92.9 million, according to the 2026-08-06 release. This supplies a cash measure alongside adjusted earnings. Company results.

Bear Case

• Quarterly growth does not prove expansion. Q2 revenue grew 49% while adjusted EBITDA grew 43%, according to the 2026-08-06 release. Those reported growth rates do not support the claim that quarterly adjusted profit grew faster than revenue. Company results.
• Revenue missed the published comparison. Benzinga’s 2026-08-06 earnings coverage reported revenue of $972.520 million against consensus of $985.716 million. The next report therefore has a concrete revenue test as well as a profit test.
• Debt accompanies the growth model. The 2026-06-30 balance sheet reported $882.7 million of long-term debt, net, against $400.8 million of cash and equivalents. An inference that financing could constrain expansion would require evidence such as refinancing pressure or an issuance; the balances alone do not establish distress. Company results.

Setup & Price Structure

The supplied adjusted series places the 2026-09-11 close of $37.98 at 23.8% below its $49.81 trailing 52-week high. Together with the three-month decline and RSI of 38.4, this supports a weak-momentum characterization. Moving-average values and participation statistics are missing, so neither an established base nor a crowded advance can be demonstrated.

The observable coverage evidence is disagreement: Truist’s $55 target was reported on 2026-08-11, while the Argus quantitative listing dated 2026-09-09 lowered its target to $40. These are third-party forecasts, not measured demand. The available coverage sample is too small to support a retail-crowding claim. Truist coverage, Argus listing.

Catalyst Calendar (next 30 days)

• 2026-09-13 through 2026-10-13: No upcoming operating event is listed on Astrana’s investor calendar as checked on 2026-09-13. A confirmed earnings date within this interval would overturn that calendar assessment. Investor calendar.
• 2026-09-30: The quarter covered by the company’s 2026-08-06 Q3 guidance ends. This is the measurement period’s endpoint, not a scheduled results announcement. Filed guidance.
• ~2026-11-05, est.: Q3 results remain the decisive operating test beyond the next month. This is an unconfirmed estimate retained from the 2026-09-05 published coverage; Astrana’s calendar had not scheduled the report as of 2026-09-13. Investor calendar.

What Would Change Our Mind

Failure of the early-August recovery would end the market thesis: a weekly close below $34 is the published research boundary. Before that breach, Q3 revenue and adjusted EBITDA meeting the 2026-08-06 guidance floors, with full-year adjusted EBITDA guidance maintained, would satisfy the operational case. Revenue below $1.000 billion accompanied by a reduction in the $255–280 million full-year adjusted EBITDA range would independently break the operating thesis. Filed guidance.

Correlation Notes

This remains a single-company setup. The 2026-09-11 evidence includes Astrana’s price measures but no matched peer-return series, so it supports no measured sector-correlation claim. Medical-cost exposure is a business-channel inference from the full-risk care model described in the 2026-08-06 investor materials; company disclosures showing medical-cost deterioration alongside weaker profit guidance would establish that channel more directly than a simultaneous move in managed-care shares.